25 results
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome ... Behcets #disease #Syndrome ... #Treatment #management ... #pharmacology # ... rheumatology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... Diagnosis and Management ... = funny-shaped cells ... Myelodysplastic #Syndrome ... #treatment #hematology
Acquired von Willebrand Syndrome - Diagnosis and Management
 • Autoantibodies to vWF: Lymphoproliferative disorders (e.g. lymphoma,
von Willebrand Syndrome ... Diagnosis and Management ... adsorption onto cancer cells ... vonWillebrand #Syndrome ... #treatment #hematology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
CD4 count <100 cells ... CD4 count >100 cells ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
Constitutional Syndromes ... Constitutional Syndromes ... marrow-failure syndromes ... Anemia #oncology #hematology ... #diagnosis #management
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Treating Isospora belli ... Infection General Management ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Leukostasis vs Tumor Lysis Syndrome
Leukostasis:
 • Pathophysiology: Large, immature blasts and high WBC count cause hyperviscosity
vs Tumor Lysis Syndrome ... hyperviscosity syndrome ... Lysis of tumor cells ... TLS #diagnosis #management ... #hematology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
CD4 count <200 cells ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
-6 activates T cells ... Cytokine Activation Syndrome ... Siltuximab #COVID19 #Pharmacology ... #Management #Medications
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Release from blast cells ... Differentiation #Syndrome ... APML #diagnosis #management ... #hematology #oncology